Peter Cain
5 Papers
1 Citations
Peter Cain is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke: a systematic review and economic evaluation.
TL;DR: The results indicate that implantable cardiac monitors could be considered cost-effective at a £20,000-30,000 threshold, and a two-stage de novo economic model was developed that captured the lifetime costs and benefits of patients on either anticoagulation or antiplatelet treatment.
23
Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study.
Steven J Edwards,Samantha Barton,Mariana Bacelar,Charlotta Karner,Peter Cain,Victoria Wakefield,Gemma Marceniuk +6 more
TL;DR: In this paper, a de novo economic model was developed to compare the costs and consequences of two treatment approaches -the 'top-down' and'step-up' strategies, with step-up considered standard care - in people at high risk of following a severe course of Crohn's disease.
2
PCR122 A Time Trade-Off Study to Determine Health-State Utilities of Transplant Recipients with Resistant or Refractory Cytomegalovirus
TL;DR: In this paper , the authors present evidence on the health-related quality of life (HRQoL) of people living with refractory/resistant CMV post-transplant.
1
Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.
Steven J Edwards,Victoria Wakefield,Peter Cain,Charlotta Karner,Kayleigh M Kew,Mariana Bacelar,Natalie Masento,Fatima Salih +7 more
TL;DR: The economic analysis, using drug list prices, shows that everolimus may be more cost-effective than BSC with an incremental cost-effectiveness ratio (ICER) of £45,000 per quality-adjusted life-year (QALY), as it is likely to be considered an end-of-life treatment.
EE571 Cost-Effectiveness of Maribavir for Post-Transplant Refractory Cytomegalovirus Infection With or Without Resistance: A UK Perspective
E. Chowdhury,T. de Lacey,R. Ressa,Jean-Etienne Poirrier,Peter Cain,Elisabetta Fenu,SL Amorosi +6 more
TL;DR: In this article , the authors investigated the cost-effectiveness of maribavir versus IAT for treatment of post-transplant R/R CMV infection in SOT/HCT recipients.